Phase 1 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 75 years old.
- People with a good general health and activity level (rated as fully active or restricted only in physically demanding activity, confirmed with trial site).
- People who have been diagnosed with a specific type of pancreatic cancer (pancreatic ductal adenocarcinoma) confirmed by a tissue test, had surgery that removed all visible cancer (R0 resection), are at stage I to III, and did not receive treatment before surgery.
- People whose bone marrow and major organs (such as liver and kidneys) are functioning at an adequate level.
- People of childbearing potential who agree to use appropriate contraception before and during the study.
- People who have signed a consent form agreeing to take part.
- People who are able to follow the study schedule and attend follow-up appointments.
Who may not be able to join:
- People who received cancer treatments such as chemotherapy, radiation, or immunotherapy within 2 weeks before the first vaccination.
- People who have had another type of cancer, unless it was certain early-stage or cured cancers (such as cervical cancer in situ, treated skin cancers, or other cancers fully treated at least 5 years ago).
- People with serious uncontrolled health conditions, including active bacterial or fungal infections, heart failure, unstable chest pain, or irregular heartbeat.
- People with HIV, active hepatitis B, or hepatitis C infection.
- People with uncontrolled heart disease, uncontrolled asthma, uncontrolled stroke-related conditions, or other conditions the trial doctor considers make participation unsafe.
- People with autoimmune diseases or immune system disorders who are currently taking medication that suppresses the immune system.
- People who are pregnant or breastfeeding.
- People who have received any other preventive vaccine within 4 weeks before the first dose, or who plan to receive one during the study or within 8 weeks after the last dose.
- People who have had a severe allergic reaction to any vaccine in the past.
- People who may be allergic to the trial vaccine or any of its ingredients.
- People with substance use issues, or those for whom participation may not be appropriate due to psychological or social factors.
- People who have lost 10% or more of their body weight in the 6 weeks before enrolling.
- People with any other uncertain factors that the trial team believes could affect their safety or ability to participate.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: zhong Wu, MD, West China Hospital
Phone: 028-85422851
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
18-month RFS; Incidence of Treatment-Related Adverse Events [Safety and Tolerability]
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.